Day One Biopharmaceuticals, Inc. (DAWN)

NASDAQ:
DAWN
| Latest update: Mar 9, 2026, 6:50 PM

Price Chart

$21.29

0.39%
(1 month)

Top Shareholders

BlackRock, Inc.
8.61%
Atlas Venture Advisors, Inc.
6.25%
The Vanguard Group, Inc.
6.12%
FMR LLC
5.57%
Vestal Point Capital LP
5.06%
State Street Corp.
4.18%
Flynn Management LLC
3.63%
Rubric Capital Management LP
3.33%

Sentiment for DAWN

News
Social

Buzz Talk for DAWN

Today

Social Media

General

Stock events for Day One Biopharmaceuticals, Inc. (DAWN)

Day One Biopharmaceuticals' stock has been impacted by several key events, including its acquisition by Servier for $2.5 billion, strong financial results and outlook with significant revenue growth, a Q4 2025 earnings miss, M&A speculation, the acquisition of Mersana Therapeutics, and insider selling by Michael Vasconcelles.

Demand Seasonality affecting Day One Biopharmaceuticals, Inc.’s stock price

While oncology prescribing patterns can experience typical holiday seasonality, Day One Biopharmaceuticals' product, OJEMDA, demonstrated resilience. Prescription volumes for OJEMDA increased in Q4 2025 despite these seasonal trends, indicating strong and consistent patient demand.

Overview of Day One Biopharmaceuticals, Inc.’s business

Day One Biopharmaceuticals, Inc. is focused on developing targeted therapies for genetically defined cancers, particularly in pediatric oncology. Its major product candidates include Tovorafenib (OJEMDA), an oral kinase inhibitor in Phase II and III trials with significant commercial success; Pimsertib, an oral MEK inhibitor; DAY301, a PTK7-targeted antibody-drug conjugate in Phase 1a trials; and Emi-Le, an antibody-drug conjugate targeting B7-H4 in Phase 1 trials.

DAWN’s Geographic footprint

Day One Biopharmaceuticals, Inc. is headquartered in Brisbane, California, United States, and plans to expand OJEMDA commercially beyond the U.S. through global partnerships.

DAWN Corporate Image Assessment

Day One Biopharmaceuticals has maintained a largely positive brand reputation, with analysts giving eight "Buy" ratings and one "Hold" rating. The company's reputation is bolstered by the strong commercial performance of OJEMDA, the acquisition of Mersana Therapeutics, and the acquisition offer by Servier.

Ownership

Day One Biopharmaceuticals, Inc. has significant institutional ownership, with 246 institutional owners holding a total of 85,384,436 shares, including major holders like BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, and Vanguard Group Inc. Significant individual and insider owners include Ai Day1 LLC and Julie Grant Papanek.

FAQ

What is the current stock price of Day One Biopharmaceuticals, Inc.?

As of the latest update, Day One Biopharmaceuticals, Inc.'s stock is trading at $21.29 per share.

What’s happening with Day One Biopharmaceuticals, Inc. stock today?

Today, Day One Biopharmaceuticals, Inc. stock is up by 0.39%, possibly due to news.

What is the market sentiment around Day One Biopharmaceuticals, Inc. stock?

Current sentiment around Day One Biopharmaceuticals, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Day One Biopharmaceuticals, Inc.'s stock price growing?

Over the past month, Day One Biopharmaceuticals, Inc.'s stock price has increased by 0.39%.

How can I buy Day One Biopharmaceuticals, Inc. stock?

You can buy Day One Biopharmaceuticals, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol DAWN

Who are the major shareholders of Day One Biopharmaceuticals, Inc. stock?

Major shareholders of Day One Biopharmaceuticals, Inc. include institutions such as BlackRock, Inc. (8.61%), Atlas Venture Advisors, Inc. (6.25%), The Vanguard Group, Inc. (6.12%) ... , according to the latest filings.